James Andra, Matchar David B, Myers Evan R
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Obstet Gynecol. 2004 Aug;104(2):381-8. doi: 10.1097/01.AOG.0000133487.55682.7b.
To review the evidence supporting screening of adult women with menorrhagia for von Willebrand disease.
MEDLINE search from January 1,1990, to December 31, 2003, for articles in English, using keywords "menorrhagia," "von Willebrand disease," "diagnosis," and "screening," with a hand-search of bibliographies of identified articles, review of published abstracts, and discussion with experts.
One hundred seven articles meeting search criteria were reviewed. Articles included in the study were those that provided primary data on the prevalence of von Willebrand disease in adult women with menorrhagia, quality of life, surgical complications, and the effectiveness of medical therapy in women with menorrhagia and von Willebrand disease and test characteristics of screening tests for von Willebrand disease.
TABULATION, INTEGRATION, AND RESULTS: The reported prevalence of von Willebrand disease in women with menorrhagia ranged from 5-20% in 5 published studies. Comparison of results was limited by small sample sizes and large confidence intervals, as well as differences in the definitions of menorrhagia and von Willebrand disease used in the studies. Although menorrhagia in women with known von Willebrand disease has a substantial impact on quality of life, there are no data suggesting that this impact is substantially greater than that of menorrhagia in women without von Willebrand disease. Data on the risk of surgical bleeding in women with von Willebrand disease are limited, with only 3 studies with a total of 29 patients identified. Data on the effectiveness of specific therapies are also limited; only one controlled trial was identified. Of single tests for screening, one study of the ristocetin cofactor assay had a sensitivity of 79% and specificity of 90%. Studies of a test of platelet adhesion and aggregation resulted in pooled sensitivities of 83-94% and specificities of 80-88%; however, significant heterogeneity was present.
There are inadequate data to justify routine testing for von Willebrand disease in adult women with menorrhagia outside of the research setting.
回顾支持对月经过多成年女性进行血管性血友病筛查的证据。
检索1990年1月1日至2003年12月31日期间MEDLINE收录的英文文章,使用关键词“月经过多”“血管性血友病”“诊断”和“筛查”,并人工检索已识别文章的参考文献、查阅已发表的摘要以及与专家进行讨论。
对符合检索标准的107篇文章进行了回顾。纳入本研究的文章是那些提供了关于月经过多成年女性血管性血友病患病率的原始数据、生活质量、手术并发症以及月经过多合并血管性血友病女性的药物治疗效果和血管性血友病筛查试验的检测特征的数据。
制表、整合与结果:5项已发表研究报告的月经过多女性中血管性血友病的患病率在5%至20%之间。由于样本量小、置信区间大以及各研究中月经过多和血管性血友病定义的差异,结果比较受到限制。尽管已知患有血管性血友病的女性月经过多对生活质量有重大影响,但没有数据表明这种影响比无血管性血友病女性的月经过多影响大得多。关于血管性血友病女性手术出血风险的数据有限,仅识别出3项共29例患者的研究。关于特定疗法有效性的数据也有限;仅识别出1项对照试验。在单一筛查试验中,一项关于瑞斯托霉素辅因子测定的研究敏感性为79%,特异性为90%。血小板黏附和聚集试验的研究汇总敏感性为83%至94%,特异性为80%至88%;然而,存在显著异质性。
在研究环境之外,没有足够的数据支持对月经过多成年女性进行血管性血友病的常规检测。